The investigators will study SPECT imaging of radiopharmaceutical therapies given as standard of care or as part of other compatible research protocols. The goal is to validate the quantitative SPECT image reconstruction methods developed in this proposal, and to investigate the relation between dosimetry calculated from SPECT images and the outcomes. Patients will be recruited for SPECT/CT imaging during treatment. This is an observational study no additional new drugs or activities will be administrated. The investigators will perform SPECT imaging on a total of 80 patients (
20 each from year 2 to year 5). Each participant will be imaged 3 times after the first and last cycles of planned radiopharmaceutical therapy.

Start Date03 Feb 2025

Sponsor / Collaborator

The Sidney Kimmel Comprehensive Cancer Center

[+1]

CTIS2024-518985-29-02

/ Active, not recruitingPhase 1/2IIT

DUET-study: A FEASIBILITY STUDY OF 177LU-PSMA RADIOLIGAND THERAPY ALTERNATED WITH RADIUM-223 IN PATIENTS WITH BONE-METASTATIC, OLIGO-METASTATIC HORMONE-SENSITIVE PROSTATE CANCER AFTER CURATIVE THERAPY.

Start Date21 Nov 2024

Sponsor / Collaborator-

NCT05924672

/ RecruitingPhase 2IIT

Efficacy of Ra-223 in PSMA PET Optimally Selected Patients

This phase II trial studies how well prostate-specific membrane antigen (PSMA) positron emission tomography (PET) scans (in combination with bone scans) work in selecting patients for Ra-223 radiation therapy that have castration-resistant prostate cancer that has spread from where it first started (primary site) to the bones (bone metastasis). Ra-223 is a type of therapy that emits radiation. Radiation gives off energy which can kill tumor cells and other cells that may support the tumor cells. Ra-223 is given by infusion into the veins, where it is absorbed by the bones. PSMA PET is a type of scan used to detect prostate cancer tumors. PSMA is a radioactive tracer that binds to a specific protein that is found on prostate tumor cells. The PSMA tracer shows the areas on the PET scan where tumor cells are active. A PET scan uses a special camera to detect the energy given off from radioactive tracers (such as PSMA) to make detailed pictures of areas where the tracer accumulates in the body. The PET scan is often combined with a magnetic resonance imaging (MRI) or computed tomography (CT) scan, which helps to map the locations where PSMA has accumulated. PSMA PET scans may be able to select patients that will benefit the most from Ra-223 treatment.

Start Date30 Aug 2024

Sponsor / Collaborator

The University of California, San Francisco

[+1]

100 Clinical Results associated with Radium Ra-223 Dichloride

100 Translational Medicine associated with Radium Ra-223 Dichloride

100 Patents (Medical) associated with Radium Ra-223 Dichloride

952

Literatures (Medical) associated with Radium Ra-223 Dichloride

01 Dec 2025·The French journal of urology

French recommendations from the AFU Cancer Committee for prostate cancer: 2025 summary of changes

Review

Author: Dariane, Charles ; Peyrottes, Arthur ; Neuzillet, Yann ; Sargos, Paul ; Brureau, Laurent ; Rozet, François ; Ploussard, Guillaume ; Fromont, Gaëlle ; Barret, Eric ; Baboudjian, Michaël ; Turpin, Léa ; Rouprêt, Morgan ; Renard-Penna, Raphaële ; Roubaud, Guilhem ; Supiot, Stéphane ; Olivier, Jonathan ; Mathieu, Romain ; Fiard, Gaëlle

PURPOSE OF THIS DOCUMENT:

The Oncology Committee of the French Urology Association (CCAFU) is proposing a 2025 summary of recommendations' changes for the management of prostate cancer (PCa).

METHODS:

A systematic review of the literature from July 2024 to September 2025 was conducted by the CCAFU on the evolutions of diagnostic and therapeutic management of PCa evaluating the newly published references with their level of evidence.

RESULTS:

Biparametric MRI is an alternative to multiparametric MRI imaging to guide biopsy decision making provided that a high-quality imaging and radiology expertise is achieved. Transperineal biopsy is the recommended approach when technically feasible. Whole-gland HIFU in patients fulfilling the HIFI trial criteria is a treatment option for intermediate-risk PCa patients. In case of metastasis-directed therapy outside the context of symptoms for oligometastatic hormone-sensitive PCa (mHSPC) disease, at least 6 months of androgen deprivation therapy (ADT) should be given. In patients with high-risk BCR treated according to the EMBARK criteria, systemic treatment with monotherapy enzalutamide may be considered. The ARPI used in addition to ADT alone can be: abiraterone, apalutamide, darolutamide, enzalutamide. In the case of HRR alterations, the combination of niraparib and abiraterone may be proposed as first-line mHSPC. In the case of a positive radiolabelled PSMA ligand PET/CT scan in a patient progressing after at least one ARPI, internal radiotherapy using [¹⁷⁷ Lu]LuPSMA-617 may be proposed. In patients with no or mildly symptomatic bone metastatic castration-resistant PCa without visceral metastases, the combination of enzalutamide+6 cycles of radium-223 may be proposed.

CONCLUSION:

This 2025 summary of changes of French recommendations on PCa should help physicians to stay up-to-date with recent evolutions and aim to improve the management of PCa patients.

01 Dec 2025·NUCLEAR MEDICINE COMMUNICATIONS

UK real-world data of radium-223 dichloride in metastatic prostate cancer

Article

Author: Logue, John ; Stratton, Irene M. ; Buchanan, Gail ; Bottomley, David ; McGrane, John ; O’Sullivan, Joe M. ; Sweeney, Loretta ; Jones, Rob J. ; Jiang, Xue ; Robinson, Angus ; Race, Gemma ; Sundar, Santhanam ; Mclaren, Duncan B. ; Stevenson, Robert ; Randhawa, Manreet ; Khoo, Vincent ; Challapalli, Amar ; McPhail, Neil ; Mazhar, Danish

Objectives:

To evaluate the treatment patterns and outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride in the UK.

Methods:

Patients initiating treatment with radium-223 from 1 September 2017 to 1 September 2019 in 15 UK oncology centres were included. Demographics, treatment, clinical, biochemical, and outcome data were collected prospectively. Quality of life data were obtained using analgesic scores and components of the Functional Assessment Cancer Therapy – Prostate (FACT-P) questionnaire.

Results:

A total of 550 consecutive, evaluable patients were included. The most common prior therapy for mCRPC was enzalutamide. At final analysis, after a median follow-up of 13.3 months, 55% of patients had completed six cycles of treatment. Median overall survival was 13.7 months (95% confidence interval, 12.6–14.8 months). Poor performance status, prior use of docetaxel in the metastatic hormone sensitive prostate cancer (mHSPC) setting, number of lines of prior treatment, and abnormal platelet count were independent variables associated with poor prognosis. Adverse events led to treatment discontinuation in 5.5% of patients. WHO analgesic scores and FACT-P questionnaire scores did not significantly change after treatment administration.

Conclusion:

The National Radium-223 Dichloride Audit was the first and largest multicentre prospective analysis of treatment patterns, outcomes, and quality of life data in patients treated with radium-223 in the UK. Radium-223 can be administered safely to patients previously treated with other life-prolonging therapies. Efficacy and safety data compare favourably with clinical trial and other real-world data. Our results suggest that its use earlier in the treatment pathway is associated with longer survival.

01 Nov 2025·LANCET ONCOLOGY

Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial

Article

Author: MacFarlane, Lisa ; Buteau, James P ; Au, Lewis ; Cardin, Anthony ; Hamilton, Anthony J ; Garcia, Quinn ; Emmerson, Brittany ; Hofman, Michael S ; Haskali, Mohammad B ; Saghebi, Javad ; Alipour, Ramin ; Parker, Belinda S ; Tran, Ben ; Kong, Grace ; Chin, Kwang Y ; Kostos, Louise ; Jackson, Price A ; Murphy, Declan G ; Kashyap, Raghava K ; Ravi Kumar, Aravind S ; Xie, Jing ; Furic, Luc ; Azad, Arun A ; Wang, Yang ; Chan, Joanna ; Akhurst, Tim

BACKGROUND:

Lutetium-177 [¹⁷⁷Lu]Lu-PSMA-I&T (¹⁷⁷Lu-PSMA-I&T) and the bone-seeking α-emitter radium-223 (²²³Ra) are established life-extending therapies for patients with metastatic castration-resistant prostate cancer; however, resistance and progression are inevitable. We aimed to evaluate the safety and preliminary antitumour activity of ¹⁷⁷Lu-PSMA-I&T combined with ²²³Ra in this patient group.

METHODS:

We conducted an investigator-initiated, single-centre, single-arm, phase 1/2 trial (AlphaBet) at the Peter MacCallum Cancer Centre in Melbourne, Australia. Adults (aged ≥18 years) with a diagnosis of progressive, metastatic castration-resistant prostate cancer, an Eastern Cooperative Oncology Group performance status score of 0-2, at least two visible bone metastases not treated with radiotherapy, previous exposure to an androgen receptor pathway inhibitor, prostate-specific membrane antigen (PSMA)-positive disease (defined by maximum standardised uptake value ≥20 at a site of disease), and no discordant sites (ie, avid on 2-[¹⁸F]fluoro-2-deoxy-D-glucose-PET-CT with minimal PSMA expression and no uptake on bone scintigraphy) were eligible for inclusion. Phase 1 dose-escalation assessed two dose levels of ²²³Ra (27·5 kBq/kg and 55·0 kBq/kg) combined with 7·4 GBq ¹⁷⁷Lu-PSMA-I&T, administered intravenously every 6 weeks for up to six cycles. Phase 2 dose expansion continued with the recommended phase 2 dose. Co-primary endpoints were the maximum tolerated or administered dose and the recommended phase 2 dose (phase 1), and the PSA response rate (phase 2), analysed in all patients treated at the maximum tolerated or administered dose in either phase. Safety was assessed in all patients who received at least one dose of either protocol treatment in phase 1 or 2. Herein, we report the results of an interim analysis, which was added to the protocol following an amendment on May 30, 2024. This trial is registered at ClinicalTrials.gov (NCT05383079) and follow-up is ongoing.

FINDINGS:

Between Nov 3, 2022, and Nov 5, 2024, 37 patients were enrolled, of whom 36 (97%; median age 72·5 years [IQR 67·0-78·0]) were included in the safety analysis and 33 (89%) were included in the preliminary activity analysis. No dose-limiting toxicities were observed. The recommended phase 2 dose of ²²³Ra was 55·0 KBq/kg combined with 7·4 GBq ¹⁷⁷Lu-PSMA-I&T, administered every 6 weeks. With a median follow-up of 13·3 months (IQR 8·7-17·1), 11 (31%) patients completed all six cycles of both treatments. 18 (50%) patients discontinued treatment early, primarily due to unequivocal disease progression (11 [61%]) or adverse events (three [17%]). A reduction in PSA of at least 50% was observed in 18 (55%; 95% CI 36-72) patients. Grade 3 or higher treatment-related adverse events occurred in five (14%) of 36 patients, including anaemia (four [11%]) and neutropenia (three [8%]), with no treatment-related deaths. Non-clinically significant grade 3 lymphopenia occurred in ten (28%) patients.

INTERPRETATION:

The combination of ¹⁷⁷Lu-PSMA-I&T and ²²³Ra is safe and feasible in patients with metastatic castration-resistant prostate cancer and bone metastases. These findings warrant further evaluation of combined α-emitting and β-emitting approaches.

FUNDING:

Prostate Cancer Foundation, Bayer, and National Health and Medical Research Council.

News (Medical) associated with Radium Ra-223 Dichloride

29 Jul 2025

·www.biopharmadive.com

Radiopharma startup Artbio secures $132M to fund testing of Pluvicto rival

Artbio on Tuesday said it has added $132 million in venture funding to advance it pipeline of radiopharmaceutical drugs for cancer and grow a manufacturing network to support their production.Based in Cambridge, Massachusetts, and Oslo, Norway, and led by former Novartis executive Emanuele Ostuni, Artbio is working on several radiopharmaceuticals. The furthest along is a program called AB001, which the company is developing for metastatic castration-resistant prostate cancer. Artbiosaid it will use some of its new funding to get AB001 through mid-stage clinical trials.Radiopharmaceuticals are designed to precisely deliver radiation into tumors. After decades of research, theyve become a buzzing area of oncology research, thanks to technical advances as well as the clinical and commercial success of Novartis prostate cancer drug Pluvicto. More than a dozen startups have formed in recent years to develop radiopharmaceuticals. Multiple companies have been acquired by large drugmakers.While many of these companies are focused on similar cancer targets, theyre using different tools, such as an different radioactive isotopes or targeting molecules.For example, Pluvicto and Bayers Xofigo, an older radiopharmaceutical for prostate cancer, are built around the isotopes lutetium-177 and radium-223, respectively. AB001 instead shepherds a lead-based radioactive isotope called Pb-212 that Artbio believes can more quickly deliver radiation to tumors. Ostuni said that the drug could provoke a more durable and efficacious response in metastatic castration-resistant prostate cancer patients.Testing remains very early. Results from a small, first-in-human trial primarily evaluating safety were published in the Journal of Nuclear Medicine in May. A Phase 1 trial will begin imminently this year, said Ostuni.But Artbio is already building enough production capacity to support global studies and, eventually, commercialization. Moving quickly on manufacturing is vital because supplies of radioactive materials are limited, and the drugs have to be made and delivered via an intensive supply chain.Artbio also touts a technology that can help simplify the generation of isotopes, which Maha Katabi, a general partner at Sofinnova Investments, described in a statement as a game-changer for navigating around supply and production challenges.It's important that we don't just build a great molecule and a great clinical development program, said Ostuni, but we also build the technology to isolate the isotope and manufacture the drug product.Since its founding, Artbio has established partnerships with biotech Parabilis formerly known as FogPharma AlphaGen Therapeutics and 3B Pharmaceuticals. The company raised $90 million in Series A funding in 2023.Sofinnova Investments and B Capital led the Series B round announced Tuesday. F-Prime Capital, Omega Funds, Third Rock Ventures, Qatar Investment Authority and Alexandria Venture Investments also participated. '

Radiation TherapyAcquisition

22 Jul 2025

·www.globenewswire.com

Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

SYDNEY, July 22, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce the appointment of Dr Oliver Sartor, MD to the Company’s Scientific Advisory Board (SAB). Dr Sartor is an internationally recognised medical oncologist and scientist specialising in prostate cancer and radiopharmaceutical therapies. He currently serves as Director of Radiopharmaceutical Clinical Trials and Chair of the Genitourinary Cancer Disease Group at the world-renowned Mayo Clinic, in Rochester, Minnesota. He was previously Laborde Professor of Medicine and Urology and Medical Director of Tulane Cancer Center in New Orleans under Tulane University School of Medicine. Dr Sartor has also held senior roles at LSU Health Sciences Center, Dana‑Farber/Harvard Medical School, and as Medical Oncology Co‑Chair of the GU Committee of NRG Oncology. Dr Sartor received his MD with honours from Tulane University School of Medicine in 1982, completed internal medicine residency at Tulane, and a medical oncology fellowship at the National Cancer Institute (NCI). Since 1990 he has focused on prostate cancer clinical research, authoring more than 500 peer‑reviewed publications and leading multiple pivotal Phase 3 trials that resulted in FDA approvals for therapies including samarium‑153 EDTMP, cabazitaxel, radium‑223, and PSMA‑targeted radioligand therapy. “Dr Sartor brings an unparalleled depth of expertise in both clinical translation and radiopharmaceutical therapies,” said Riccardo Canevari, Managing Director and CEO of Radiopharm Theranostics. “We’re very honoured to welcome him to our SAB. His insight and leadership will be invaluable as we advance our radiopharmaceutical pipeline.” About Radiopharm Theranostics Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and three Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain metastases. Learn more at radiopharmtheranostics.com. Authorized on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman Paul Hopper. For more information: Investors:Riccardo CanevariCEO & Managing DirectorP: +1 862 309 0293E: rc@radiopharmtheranostics.com Anne Marie Fields Precision AQ (Formerly Stern IR) E: annemarie.fields@precisionaq.com Media:Matt WrightNWR CommunicationsP: +61 451 896 420E: matt@nwrcommunications.com.au Follow Radiopharm Theranostics: Website – https://radiopharmtheranostics.com/ Twitter – https://twitter.com/TeamRadiopharm Linked In – https://www.linkedin.com/company/radiopharm-theranostics/InvestorHub – https://investorhub.radiopharmtheranostics.com/

Executive ChangePhase 1Phase 3

09 Jul 2025

·www.biopharmadive.com

Actithera draws new investors to radiopharma drug pitch

Dive Brief:Actithera, a radiopharmaceutical drugmaker based in Oslo, Norway and Cambridge, Massachusetts, has raised just under $76 million in Series A venture financing to build out its cancer drug pipeline.In a Wednesday statement, the biotechnology company said it would use the new funds to advance into clinical development an experimental treatment targeting what are known as fibroblast activation proteins.M Ventures, which helped found the company in 2021, co-led the Series A round with Hadean Ventures, Sofinnova Partners and 4BIO Capital. Five other firms also participated.Dive Insight:Radiopharmaceuticals offer a better way to target tumor-killing radiation more precisely to cancerous cells and, accordingly, theyve drawn rising interest from drugmakers. The technology works by attaching a radioisotope to a targeting compound via a specially engineered linker molecule.While radiopharmaceuticals have been around for years Bayers Xofigo was approved in the U.S. in 2013 the field has taken off since the success of Novartis prostate cancer treatment Pluvicto. The drug earned Novartis more than $1.3 billion in 2025, giving the industry a glimpse of radiopharmaceuticals sales potential.Other large companies, like Bristol Myers Squibb and Eli Lilly, have entered the field with acquisitions of earlier-stage public biotechs.Private radiopharma companies, meanwhile, drew more than $1.1 billion since 2022 from a group of 23 venture firms tracked by BioPharma Dive.Actithera is designing its cancer drugs so they can stay in a tumor for longer by binding tightly to proteins that help a tumor grow. Founded by Andreas Goutopoulos, a veteran of Merck KGaAs U.S. subsidiary EMD Serono Inc., the biotech is focused first on an enzyme called fibroblast activation protein, or FAP.Andreas Goutopoulos, a veteran of a U.S. subsidiary of Merck KGaA, is the founder of radioligand therapy developer Actithera.Permission granted by ActitheraThe protein is expressed on cells that form connective tissue, but in cancer can support tumor growth. Actithera aims to eliminate those proteins and cancer-associated fibroblasts in a cross-fire effect that kills nearby tumor cells, Goutopoulos said.Its a way to dismantle a critical barrier to immune and therapeutic access, he wrote in an email to BioPharma Dive.Radiopharmaceuticals can be tricky to develop. Manufacturing is complex and expensive, and in response, companies like Novartis have opened dedicated production facilities. The isotope they contain also degrades over time, making the logistics of their delivery critical.Actithera is one of many up-and-coming biotechs looking to follow Novartis lead. Some of those, including Novartis and Ratio Therapeutics, are also targeting FAP.Actithera has not disclosed which cancers its targeting with its therapies. The company is preparing for clinical development in 2026 across multiple indications, Goutopoulos said.Actithera stands out as one of the most thoughtfully constructed radiopharma platforms weve seen, combining smart molecular design with a deep understanding of tumor biology and clinical need, Roger Franklin, a partner at Hadean Ventures, said in a statement. '

Drug ApprovalAcquisitionRadiation Therapy

100 Deals associated with Radium Ra-223 Dichloride

External Link

KEGG	Wiki	ATC	Drug Bank
-	Radium Ra-223 Dichloride	V10XX03	DB08913

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Prostatic Cancer	China	Institute For Energy Technology	26 Aug 2020
Bone metastases	European Union	Bayer AG	13 Nov 2013
Bone metastases	Iceland	Bayer AG	13 Nov 2013
Bone metastases	Liechtenstein	Bayer AG	13 Nov 2013
Bone metastases	Norway	Bayer AG	13 Nov 2013
Castration-Resistant Prostatic Cancer	United States	Bayer HealthCare Pharmaceuticals, Inc.	15 May 2013

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Castration-sensitive prostate cancer	Phase 3	-	Bayer AG	01 Sep 2023
Metastatic Prostate Carcinoma	Phase 3	-	Bayer AG	01 Sep 2023
Metastatic castration-resistant prostate cancer	Phase 3	United States	Bayer AG	26 Mar 2013
Metastatic castration-resistant prostate cancer	Phase 3	China	Bayer AG	26 Mar 2013
Metastatic castration-resistant prostate cancer	Phase 3	Singapore	Bayer AG	26 Mar 2013
Metastatic castration-resistant prostate cancer	Phase 3	Taiwan Province	Bayer AG	26 Mar 2013
Metastatic Prostatic Adenocarcinoma	Phase 2	United States	Bayer AG	28 Apr 2022
Metastatic Prostatic Adenocarcinoma	Phase 2	Brazil	Bayer AG	28 Apr 2022
Oligometastatic Prostate Carcinoma	Phase 2	United States	Bayer AG	27 Feb 2018
Relapse multiple myeloma	Phase 2	United States	Bayer AG	01 Oct 2016

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05383079 (AlphaBet, Pubmed \| Lancet Oncol)	Phase 1/2	Metastatic castration-resistant prostate cancer	37	radium-22377 [177Lu]Lu-PSMA-I&T + radium-223	dqxhpkwill(rlukhrsfcv) = zommxipzlx gihmlebzfp (terxaffcox, 36 - 72) View more	Positive	01 Nov 2025
ESMO2025	Not Applicable	Metastatic castration-resistant prostate cancer	65	Radium-223 (metastatic castration-resistant prostate cancer)	voccbdkgyi(quyenvrvzq) = ubhhrsluns gnveojyola (xlhlxzswjr, 6.6 - 12.0) View more	Positive	17 Oct 2025
ESMO2025	Not Applicable	Metastatic castration-resistant prostate cancer	87	Radium-223 dichloride (mCRPC with bone metastases)	prhnjnhrff(fvbhlrersx) = Hematologic toxicity was the most frequent adverse event (72.2%), with > G2 toxicity obsereved in 22.2% of cases (G3: 16.7%, G4: 5.5%) ztcmqnvzqx (wxztqhlcnr )	Positive	17 Oct 2025
ESMO2025	Not Applicable	Metastatic castration-resistant prostate cancer	79	Radium-223 dichloride (Ra-223)	imiucmahuw(uvcmnqcblt) = Treatment was discontinued for toxicity in 41%. efsbppzbrh (yvsrdnvlkq )	Positive	17 Oct 2025
NCT02141438 (REASSURE, ASCO2025)	Not Applicable	Metastatic castration-resistant prostate cancer	1,472	Radium-223	lustgrifyd(onegmmmarc) = Fractures were reported in 10% of pts and were less common in pts with (7% of 605) than without (12% of 867) concomitant BHA use ijdtzslerw (nwebxcafaj )	Positive	30 May 2025
NCT02141438 (REASSURE, ASCO2025)	Not Applicable	Metastatic castration-resistant prostate cancer	1,472	Docetaxel		Positive	30 May 2025
NCT04071236 (Phase l and randomized phase ll trial of radium-223 dichloride, peposertib, and avelumab, ASCO2025)	Phase 1/2	Metastatic castration-resistant prostate cancer	15	Radium-223 dichloride + Peposertib 200 mg PO bid	zpsosfjkzg(vsjefjxeli) = 1 patient experienced anemia ulxlckkiov (ruhhumaoqo ) View more	Positive	30 May 2025
	Phase 1/2	Metastatic castration-resistant prostate cancer	15	Radium-223 dichloride + Peposertib 200 mg PO bid + Avelumab 800 mg IV		Positive	30 May 2025
NCT02194842 (PEACE-3, ASCO2025)	Phase 3	Metastatic castration-resistant prostate cancer prostate-specific antigen \| alkaline phosphatase	446	Enzalutamide alone (ENZ)	ixwefsvuwg(jchhisofmo) = knvzjsccyi vujmqnjlzt (cuszrtjlhl, 2.99 - 14.06) View more	Positive	30 May 2025
NCT02194842 (PEACE-3, ASCO2025)	Phase 3		446	Enzalutamide combined with 6 cycles of Radium 223 (ENZ-RAD)	ixwefsvuwg(jchhisofmo) = smyxjfxzfi vujmqnjlzt (cuszrtjlhl, 1.87 - 2.50) View more	Positive	30 May 2025
NCT04037358 (RAVENS, Pubmed \| J Clin Oncol)	Phase 2	Oligometastatic Prostate Carcinoma ATM \| BRCA1/2 \| RB1 ... View more	64	Radium-223 (Stereotactic Ablative Radiation (SABR) MDT)	eijfgmnjxy(fnodcrxyhr) = crggyyyagb vhollwlqvc (msqzctryee )	Negative	07 May 2025
NCT02194842 (EORTC 1333/PEACE-3, Pubmed \| Eur Urol)	Phase 3	Fractures, Bone First line	-	Radium-223 combined with Enzalutamide	pxhmevscha(imutglzohc) = ccnxqoblci ndnfkoseuh (zjkbjhnqko )	Positive	01 Mar 2025
NCT02194842 (EORTC 1333/PEACE-3, Pubmed \| Eur Urol)	Phase 3	Fractures, Bone First line	-	Enzalutamide alone	pxhmevscha(imutglzohc) = qntppgyiev ndnfkoseuh (zjkbjhnqko )	Positive	01 Mar 2025
NCT04206319 (ASCO_GU2025)	Phase 2	Non-metastatic prostate cancer PSMA+ \| NaF+	18	Radium 223	dtujqijhke(semousnidn) = Grade 2 toxicities have been rare and no Grade 1 or 2 changes in hemoglobin or platelets have occurred edhtxxxnvg (lrpdbdqabv ) View more	Positive	13 Feb 2025

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Radium Ra-223 Dichloride

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation